oncolytic virus

ROCKVILLE, Md., August 6, 2026 Theriva Biologics announced that the first patient has been dosed in the VIRAGE2 Phase...

SAN DIEGO, July 27, 2026 Calidi Biotherapeutics presented new preclinical data from its CLD-401 program and its in situ...

PRINCETON, N.J., July 8, 2026 UroGen Pharma Ltd. announced that the U.S. Food and Drug Administration (FDA) has cleared...

SAN DIEGO, June 24, 2026 Calidi Biotherapeutics presented new preclinical data on CLD-501, its investigational in situ T-cell engager...

Woburn, Massachusetts | April 10, 2026 Replimune Group Inc. has announced that the U.S. Food and Drug Administration (FDA)...

SUZHOU, China, February 26, 2026 ImmVira Group announced encouraging preliminary clinical data for its oncolytic virus candidate MVR-T3011 in...

CALGARY, Alberta, November 4, 2025 — Oncolytics Biotech® Inc. (NASDAQ: ONCY; TSX: ONC) announced the formation of a Gastrointestinal...